(Q37895002)

English

A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project.

scientific article published on July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21708859%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

Europe PubMed Central

A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21708859%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

0 references

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Charles J. Ferro

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21708859%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

S King

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21708859%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

K Forbes

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21708859%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

G W Hanks

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21708859%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

E J Chambers

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21708859%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

1 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21708859%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Palliative Medicine

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21708859%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21708859%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21708859%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

525-552

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21708859%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Identifying patients with chronic kidney disease from general practice computer records

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Systematic comparison of four sources of drug information regarding adjustment of dose for renal function

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

An analysis of discharge drug prescribing amongst elderly patients with renal impairment

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Grading quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Opioid rotation for toxicity reduction in terminal cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Normorphine, a neurotoxic metabolite?

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Chronic nausea and morphine-6-glucuronide

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Morphine or oxycodone in cancer pain?

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Use of hydromorphone (Dilaudid) and morphine for patients with hepatic and renal impairment

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

A retrospective study of the association between haematological and biochemical parameters and morphine intolerance in patients with cancer pain

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Opioid analgesia in uraemic patients

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

A retrospective review of the use of alfentanil in a hospital palliative care setting

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Central nervous system excitatory effects of meperidine in cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Subcutaneous sufentanil for palliative care patients in a hospital setting.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Evidence based medicine: what it is and what it isn't

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Morphine and alternative opioids in cancer pain: the EAPC recommendations

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Opioid use in renal failure #161.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Drug Prescribing in Renal Failure: Dosing Guidelines for Adults

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Pharmacokinetics of opioids in renal dysfunction

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Opioids in renal failure and dialysis patients

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Analgesia in patients with ESRD: a review of available evidence

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Symptom management in patients with established renal failure managed without dialysis

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Role of active metabolites in the use of opioids

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Opioids and renal function

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

The role of morphine glucuronides in cancer pain

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Is morphine-3-glucuronide of therapeutic relevance?

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Drug metabolites in renal failure: pharmacokinetic and clinical implications

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Extrahepatic morphine metabolism in man during the anhepatic phase of orthotopic liver transplantation.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Extrahepatic metabolism of morphine occurs in humans

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Human UDP-glucuronosyltransferases: metabolism, expression, and disease

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive‐care patients

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Morphine-6-glucuronide disposition in renal impairment.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Long lasting respiratory depression induced by morphine-6-glucuronide?

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Oral morphine in cancer pain: influences on morphine and metabolite concentration

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Morphine intoxication in renal failure: the role of morphine-6-glucuronide

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Variable-dose patient-controlled analgesia. A preliminary report.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Influence of renal function on the elimination of morphine and morphine glucuronides.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Morphine-3-glucuronide--a potent antagonist of morphine analgesia

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Morphine-6-O-beta-D-glucuronide but not morphine-3-O-beta-D-glucuronide binds to mu-, delta- and kappa- specific opioid binding sites in cerebral membranes

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Morphine-6beta-glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Randomized placebo-controlled trial of the activity of the morphine glucuronides

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Limited phase I study of morphine-3-glucuronide

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Unwanted effects of morphine-6-glucoronide and morphine

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Randomized, double-blind study of the analgesic efficacy of morphine-6-glucuronide versus morphine sulfate for postoperative pain in major surgery

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

The analgesic activity of morphine-6-glucuronide

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

A randomized, double-blind, placebo-controlled pilot study of IV morphine-6-glucuronide for postoperative pain relief after knee replacement surgery

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Increased plasma morphine metabolites in terminally ill cancer patients with delirium: an intra-individual comparison

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Codeine and clinical impairment in samples in which morphine is not detected

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Affinities of dihydrocodeine and its metabolites to opioid receptors

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Opioid drugs and renal failure

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Electrophysiologic properties of propoxyphene and norpropoxyphene in canine cardiac conducting tissues in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Disposition of propoxyphene and norpropoxyphene in man after a single oral dose

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Meperidine-associated myoclonus and seizures in long-term hemodialysis patients

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Successful treatment of normeperidine neurotoxicity by hemodialysis

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Toxicity of norpethidine in sickle cell crisis

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Norpethidine induced myoclonus in a patient with renal failure

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Effects of the central analgesic tramadol and its main metabolite, O-desmethyltramadol, on rat locus coeruleus neurones

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

The pharmacology of tramadol

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Oxycodone accumulation in a hemodialysis patient

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Urinary excretion of hydromorphone and metabolites in humans, rats, dogs, guinea pigs, and rabbits

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Simultaneous determination of hydromorphone, hydrocodone and their 6alpha- and 6beta-hydroxy metabolites in urine using selected ion recording with methane chemical ionization

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Buprenorphine in end stage renal failure.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Patient-controlled analgesic infusions: alfentanil versus morphine

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

The place for short-acting opioids: special emphasis on remifentanil

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Intranasal sufentanil for cancer-associated breakthrough pain.

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Prolonged opioid antagonism with naloxone in chronic renal failure

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406313

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37895002&oldid=2107150199"